Hey, this is an English text. I want you to translate it into the Tunisian dialect. Please follow these steps:
1. Translate step by step and highlight differences between Tunisian dialect and Modern Standard Arabic.
2. Highlight sections you are confident translating into the Tunisian dialect.
Translate this text into the Tunisian dialect, focusing on capturing the essence of the language nuances:

Introduction {#Sec1} ============ Curcumin (diferuloylmethane) from turmeric plant *Curcuma longa* and its derivatives known as curcuminoids have been recognized to be effective in experimental studies for a very large number of diseases with an equally large number of diverse molecular targets^[@CR1],\ [@CR2]^. More specifically, curcumin has been tested as an anti-inflammatory agent for treatment of cancers and other diseases^[@CR3],\ [@CR4]^. Based on its immunomodulatory properties, curcumin has also been suggested as an adjunct drug for the treatment of many infectious diseases^[@CR5]^. In spite of extensive clinical trials using curcumin, and its classification as a generally recognized as safe (GRAS) molecule, it is still not an approved drug even for a single ailment^[@CR6]^. The main reasons include poor water solubility, low bioavailability, rapid metabolism and clearance from body^[@CR6],\ [@CR7]^. It has been suggested that nanocurcumin represents a promising therapeutic advancement over native curcumin^[@CR8]^. It is in this context that we want to report our results obtained with curcumin nanoparticles prepared using poly(lactide-co-glycolide) (PLGA) in comparison with native curcumin to treat experimental cerebral malaria (ECM). Human cerebral malaria (HCM) is a serious complication with high mortality (15--25%) despite the existing standard therapy using artemisinin derivatives. Hence, there is a need for adjunct therapy^[@CR9]^. Inflammation in brain, blood-brain barrier (BBB) breakdown and sequestration of parasitized-RBCs (pRBCs) are the major factors contributing to high mortality in HCM. Despite some differences, ECM in *Plasmodium berghei*-infected mice has been shown to share many features of HCM and is considered very useful to dissect the mechanisms involved and screen drug molecules^[@CR10]--[@CR12]^. Curcumin, when given orally by gavage during 0--5 days post-infection, has been shown to delay death of mice (C57BL/6) in the ECM model, reversing the symptoms of cerebral malaria^[@CR13]^. We have recently shown that native curcumin alone is effective in counteracting the neurological symptoms and inflammation parameters of ECM with a significant delay in the mortality of mice, which eventually died due to anemia caused by parasite build-up in blood^[@CR14]^. The objective of the present study was to formulate curcumin in low molecular weight PLGA-based nanoparticles (PLGA-curcumin) and evaluate its potential in ECM. PLGA polymers have been extensively used for drug and vaccine delivery^[@CR15],\ [@CR16]^. PLGA- and PLA-based polymers provide interesting features for the sustained delivery of curcumin while protecting its degradation and improving its bioavailability^[@CR17]--[@CR19]^. In a fresh set of experiments carried out in parallel, we compared the efficacies of orally administered native curcumin and PLGA-curcumin. It was observed that PLGA-curcumin was as effective as native curcumin at a 15-fold lower concentration in counteracting the neurological symptoms and inflammation parameters, and in preventing the breakdown of BBB. It was more effective than native curcumin in preventing the sequestration of lymphocytes and pRBCs in brain. PLGA-curcumin, even at a lower curcumin concentration, led to higher concentrations of curcumin in the brain than native curcumin. The results indicated that PLGA-curcumin nanoparticles have the potential to be used as adjunct therapy for treating HCM. Results {#Sec2} ======= Preparation and characterization of PLGA-curcumin {#Sec3} ------------------------------------------------- PLGA nanoparticles entrapping curcumin